Response rate accuracy in oncology trials: Reasons for interobserver variability

Journal of Clinical Oncology

Volumn 15, Issue 12, 1997, Pages 3507-3514

  Thiesse, Philippe ^a   Ollivier, Liliane ^a   Di Stefano Louineau, Donatella ^a   Négrier, Sylvie ^a   Savary, Jacqueline ^a   Pignard, Karine ^a   Lasset, Christine ^a   Escudier, Bernard ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; INTERLEUKIN 2;

ARTICLE; CANCER CONTROL; CANCER RESEARCH; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC IMAGING; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; ONCOLOGICAL PARAMETERS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0030658087     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.12.3507     Document Type: Article

References (35)

1. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
2. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva, Switzerland, World Health Organization, 1979
3. Negrier S, Escudier B, Lasset C, et al: The FNLCC CRECY trial: Interleukin 2 (IL2) + Interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 15:39, 1996 (abstr 629)
4. Fleiss JL: Statistical Methods for Rates and Proportions. New York, NY, Wiley, 1973, pp 143-147
5. Anderson J, Cain K, Gelber R, et al: Analysis and interpretation of the comparison of survival by treatment. Outcome variables in cancer clinical trials. Cancer Treat Rep 69:1139-1143, 1985
6. Laplanche A: Tumor response in comparative trials. Bull Cancer 78:687-692, 1991
7. Gurland J, Johnson RO: How reliable are tumor measurements? JAMA 194:125-130, 1965
8. Hayward JL, Carbone PP, Heuson JC, et al: Assessment of response to therapy in advanced breast cancer. Cancer 39:1289-1294, 1977
9. Watson JV: What does "response" in cancer chemotherapy really mean? Br Med J 283:34-37, 1981
10. Tannock I, Murphy K: Reflections on medical oncology: An appeal for better clinical trials and improved reporting of their results. J Clin Oncol 1:66-70, 1983
11. Davis HL, Multhauf P, Klotz J: Comparisons of cooperative group evaluation criteria for multiple drug therapy for breast cancer. Cancer Treat Rep 64:507-517, 1980
12. Atzpodien J, Körfer A, Franks CR, et al: Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies. Lancet 335:1509-1512, 1990
13. Fossa SD, Martinelli G, Otto U, et al: Recombinant Interferon α-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study. Ann Oncol 3:301-305, 1992
14. Minasian LM, Motzer RJ, Gluck L, et al: Interferon alfa-2 in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long term follow-up. J Clin Oncol 11:1368-1375, 1993
15. Negrier S, Philip T, Stoter G, et al: Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: Report of a European multicenter study. Eur J Cancer Clin Oncol 25:21-28, 1989 (suppl 3)
16. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
17. Fornage BD: Measuring masses on cross-sectional images. Radiology 187:289, 1993 (letter)
18. Grossman S, Burch P: Quantification of tumor response to anti-neoplastic therapy. Semin Oncol 15:441-454, 1988
19. Warr D, McKinney S, Tannock I: Influence of measurement error on assessment of response to anticancer chemotherapy: Proposal for new criteria of tumor response. J Clin Oncol 2:1040-1046, 1984
20. Ollivier L, Escudier B, Thiesse P, et al: Clinical trials in oncology need evaluation committees: Results from a French multicenter study. European Society of Medical Oncology, Lisboa, Portugal, November 18-22, 1994 (abstr 1092)
21. Gurland J, Johnson RO: Care for using only maximum diameter in measuring tumors. Cancer Chemother Rep 50:119-124, 1966
22. Hopper KD, Kasales CJ, Van Slyke MA, et al: Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR 167:851-854, 1996
23. Lavin PT, Flowerdew G: Studies in variation associated with the measurements of solid tumors. Cancer 46:1286-1290, 1980
24. Moertel CG, Hanley JA: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38:388-394, 1976
25. Bressler EL, Alpern MB, Glazer GM, et al: Hypervascular hepatic metastases: CT evaluation. Radiology 162:49-51, 1987
26. Dubrow RA, David CL, Libshitz HI, et al: Detection of hepatic metastases in breast cancer: The role of non enhanced and enhanced CT scanning. J Comput Assist Tomogr 14:366-369, 1990
27. Oliver JH, Baron RL: Helical biphasic contrast-enhanced CT of the liver: Technique, indications, interpretation and pitfalls. Radiology 201:1-14, 1996
28. Haase GM, Atkinson JB, Stram DO, et al: Surgical management and outcome of locoregional neuroblastoma: Comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 30: 289-294, 1995
29. Eggli KD, Close P, Dillon PW, et al: Three-dimensional quantitation of pediatric tumor bulk. Pediatr Radiol 25:1-6, 1995
30. Buthiau D, Antoine EC, Nizri D, et al: The clinical measurement of volumes using helical CT. Surg Radiol Anat 18:227-231, 1996
31. Berbaum KS, Franken EA, Dorfman DD, et al: Influence of clinical history upon detection of nodules and other lesions. Invest Radiol 23:48-55, 1988
32. Doubilet P, Herman PG : Interpretation of radiographs: Effect of clinical history. AJR 137:1055-1058, 1981
33. McNeil BJ, Hanley JA, Funkenstein HH, et al: Paired receiver operating characteristic curves and the effect of history on radiographic interpretation. Radiology 149:75-77, 1983
34. Schreiber MH: The clinical history as a factor in roentgenogram interpretation. JAMA 185:137-139, 1963
35. Giovagnoni A, Piga A, Argalia G, et al: Inadequacy of ultrasonography for monitoring response to treatment of liver metastases. J Clin Oncol 12:2451-2455, 1993